Benzinga | Oct 13, 2021 01:38PM EDT

Abeona Therapeutics Announces Clinical Data Presentations At Upcoming Scientific Congresses

Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations include a poster presentation on the long-term wound healing and pain relief data from the Phase 1/2a EB-101 trial at the 2021 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, held virtually October 14-15, 2021; and an oral presentation on the pivotal trial of the Company's investigational AAV-based gene therapy ABO-102 in MPS IIIA at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), October 19-22, 2021.



Presentation details are as follows:

Event: 2021 PeDRA Annual Conference

Title: Long-Term Healing, Pain Reduction, and Patient-Reported Outcomes in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Following EB-101 Treatment of Large, Chronic Wounds

Poster Number: 45

Event: ESGCT 28th Annual Congress

Title: Interim Results of Transpher A, a Multicentre, Single-dose, Phase 1/2 Clinical Trial of ABO-102 Investigational Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)

Talk Number: INV38

Session: 4a

Date and Time: Thursday, October 21, 2021, 9:30 am CEST